Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 12.01.2026 1 AJR Am J Roentgenol 1 Am J Clin Oncol 2 Am J Clin Pathol 1 Am J Epidemiol 1 Am J Surg 13 Ann Surg Oncol 2 BMC Cancer 2 Br J Cancer 10 Breast Cancer 4 Breast Cancer (Dove Med Press) 10 Breast Cancer Res 7 Breast Cancer Res Treat 1 Breast J 1 Cancer 1 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 3 Cancer Res 2 Clin Breast Cancer 2 Clin Cancer Res 1 Clin Exp Metastasis 1 Eur J Cancer 1 Eur J Surg Oncol 1 Exp Cell Res 1 J Clin Oncol 4 J Natl Cancer Inst 1 J Nucl Med 1 J Pathol 1 Mod Pathol 1 Mol Ther Oncol 1 Nature 1 NPJ Breast Cancer 1 Oncogene 1 Oncology 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CHEN IE, Joines M, Capiro N, Dawar R, et al
   Commercial Artificial Intelligence Versus Radiologists: NPV and Recall Rate in Large Population-Based Digital Mammography and Tomosynthesis Screening Mammography Cohorts.
   AJR Am J Roentgenol. 2025 Sep 3. doi: 10.2214/AJR.25.32889.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. QURESHI Z, Jamil A, Wali N, Okobi TJ, et al
   Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2026 Jan 6. doi: 10.1097/COC.0000000000001294.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

3. THABET DM, Thabit DM
   Immunohistochemical expression of POC1A, NUF2, and Ki-67 in invasive ductal carcinoma of the breast.
   Am J Clin Pathol. 2025;164:890-907.
   PubMed         Abstract available
   
   
4. RIDEG O, Dergez T, Toth A, Tornoczky T, et al
   Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum.
   Am J Clin Pathol. 2025;164:924-932.
   PubMed         Abstract available
   
   

   
   Am J Epidemiol

5. POWER GM, Palmer T, Warrington N, Heron J, et al
   A structural mean modelling Mendelian randomization approach to investigate the lifecourse effect of adiposity: applied and methodological considerations.
   Am J Epidemiol. 2025 Feb 17:kwaf029. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Am J Surg

6. MONTGOMERY KB, Rademacher N, Richman JS, Bhatia S, et al
   Healthcare facility volume and evidence-based practice implementation in surgical care of patients with common cancers.
   Am J Surg. 2026;252:116733.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. FISH EM, Whittall I, Lyons W, Bleicher RJ, et al
   Axillary Management Trends and Survival in Men Undergoing Mastectomy with Positive Sentinel Nodes.
   Ann Surg Oncol. 2026;33:1150-1161.
   PubMed         Abstract available
   
   
8. STURZ-ELLIS JL, Vetter CD, Day CN, Boughey JC, et al
   A Systematic Review of Occult Malignancy and Sentinel Lymph Node Metastasis at the Time of Contralateral Prophylactic Mastectomy.
   Ann Surg Oncol. 2026;33:1162-1170.
   PubMed         Abstract available
   
   
9. LUDWIG KK, Kong A, Grossi S, Joseph KA, et al
   Implementation of Quality Improvement Projects: A Practical Guide From the American Society of Breast Surgeons Patient Safety and Quality Committee.
   Ann Surg Oncol. 2026;33:1221-1231.
   PubMed         Abstract available
   
   
10. WANG T, Neish D, Thomas S, Botty van den Bruele A, et al
    ASO Visual Abstract: Radiation Deescalation in Older Women with Early Stage ER+/HER2- Invasive Breast Cancer.
    Ann Surg Oncol. 2026 Jan 3. doi: 10.1245/s10434-025-19009.
    PubMed        
    
    
11. VAN VLISSINGEN EMALCF, van der Ploeg IMC
    ASO Author Reflections: De-Escalating Internal Mammary Sentinel Node Surgery in Breast Cancer.
    Ann Surg Oncol. 2026 Jan 3. doi: 10.1245/s10434-025-18973.
    PubMed        
    
    
12. MASANAM MK, Bellon JR, Leone JP, Mittendorf EA, et al
    Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy.
    Ann Surg Oncol. 2026 Jan 3. doi: 10.1245/s10434-025-18939.
    PubMed         Abstract available
    
    
13. PARMAR P, Lin J, Bhimani F, Jao L, et al
    ASO Visual Abstract: Zip-Code-Level Disadvantage as a Predictor of Metastatic Breast Cancer at Diagnosis and Delayed Treatment Initiation.
    Ann Surg Oncol. 2026 Jan 5. doi: 10.1245/s10434-025-18860.
    PubMed        
    
    
14. VAN VLISSINGEN EMALCF, Postma EL, Scholten AN, van der Leij F, et al
    The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?
    Ann Surg Oncol. 2026 Jan 5. doi: 10.1245/s10434-025-18930.
    PubMed         Abstract available
    
    
15. BEERTHUIZEN AWJ, van Duijnhoven FH
    ASO Author Reflections: The Added Value of Axillary Ultrasound in Early Breast Cancer: Insights from the AMAROS Trial.
    Ann Surg Oncol. 2026 Jan 6. doi: 10.1245/s10434-025-18998.
    PubMed        
    
    
16. VAN GEMERT D, Beelen LM, Mos J, van Egdom L, et al
    ASO Author Reflections: Beyond Treatment Intensity: Understanding Individual Susceptibility in Breast Cancer-Related Lymphedema (BCRL).
    Ann Surg Oncol. 2026 Jan 7. doi: 10.1245/s10434-025-18851.
    PubMed        
    
    
17. WANG Z, Gu L, Yang M, Zhou Y, et al
    NUP62 Elevates USP10 Expression and Promotes Tamoxifen Resistance of Breast Cancer by Deubiquitinating ERalpha.
    Ann Surg Oncol. 2026 Jan 7. doi: 10.1245/s10434-025-18995.
    PubMed         Abstract available
    
    
18. JACINTO AI, Sauder C
    ASO Author Reflections: Treating Secondary Triple Negative Breast Cancer in Younger Women.
    Ann Surg Oncol. 2026 Jan 7. doi: 10.1245/s10434-025-19016.
    PubMed        
    
    
19. JACINTO AI, Keegan THM, Li Q, Maguire FB, et al
    Differences in Treatment and Survival for Secondary Triple Negative Breast Cancer in Premenopausal Women.
    Ann Surg Oncol. 2026 Jan 9. doi: 10.1245/s10434-025-18892.
    PubMed         Abstract available
    
    

    
    BMC Cancer

20. HUNDAL J, Williams D, Nock NL, Austin K, et al
    Older breast cancer survivors' exercise and support group program experiences and recommendations from the IMPROVE trial: a qualitative study.
    BMC Cancer. 2026 Jan 6. doi: 10.1186/s12885-025-15425.
    PubMed         Abstract available
    
    
21. YOON TI, Baek S, Lee JH, Yoo TK, et al
    Clinical significance of peripheral blood parameters as a prognostic biomarker in patients receiving neoadjuvant chemotherapy for breast cancer.
    BMC Cancer. 2026 Jan 3. doi: 10.1186/s12885-025-15510.
    PubMed        
    
    

    
    Br J Cancer

22. VALASAKI M, Taylor LC, Woof VG, Howell SJ, et al
    The breast cancer risk assessment pathway in England: a systems analysis of current challenges and ways to improve.
    Br J Cancer. 2026 Jan 6. doi: 10.1038/s41416-025-03329.
    PubMed         Abstract available
    
    
23. MICHAEL S, Broggio J, Bowers S, Ooi J, et al
    Distant recurrence and margin involvement in invasive breast cancer.
    Br J Cancer. 2026 Jan 5. doi: 10.1038/s41416-025-03275.
    PubMed         Abstract available
    
    

    
    Breast Cancer

24. CARAMELO O, Almeida V, Fidalgo A, Cipriano A, et al
    Prognostic relevance of specific TIL (CD4+, CD8+, and FOXP3 + T-cell infiltrates) in triple-negative breast cancer: short- and long-term outcomes.
    Breast Cancer. 2026 Jan 7. doi: 10.1007/s12282-025-01819.
    PubMed         Abstract available
    
    
25. SEKI H, Watanabe N, Nagura N, Ogiya A, et al
    Safety of radiotherapy in patients undergoing breast reconstruction based on patient-reported outcomes: a multicenter collaborative study.
    Breast Cancer. 2026;33:304-312.
    PubMed         Abstract available
    
    
26. ZHANG G, Yang L, Xu F, Luo Q, et al
    Adjuvant radiotherapy and survival in patients with malignant phyllode tumors: a population-based retrospective study.
    Breast Cancer. 2026;33:260-268.
    PubMed         Abstract available
    
    
27. SATO K, Fuchikami H, Takeda N, Natsume N, et al
    Patterns of ipsilateral breast tumor recurrence following partial vs. whole-breast irradiation: a retrospective comparative study of breast-conserving therapy.
    Breast Cancer. 2026;33:251-259.
    PubMed         Abstract available
    
    
28. HORIMOTO Y, Kaise H, Ishikawa T, Sato E, et al
    Current practices and challenges in margin evaluation for breast-conserving surgery specimens: a nationwide survey in Japan with international benchmarking.
    Breast Cancer. 2026;33:236-242.
    PubMed         Abstract available
    
    
29. GOTO D, Oshima A, Onishi T, Higashino T, et al
    "Safety and efficacy of early drain removal in breast reconstruction: a retrospective cohort study".
    Breast Cancer. 2026;33:217-226.
    PubMed         Abstract available
    
    
30. MARINIELLO MD, Roncella M, Mazzotta D, Gerges I, et al
    Scaffold-based breast conserving surgery in patients with non-malignant breast lesions: long-term follow-up of a first-in-human pilot study on the REGENERA biomimetic breast implant.
    Breast Cancer. 2026;33:111-122.
    PubMed         Abstract available
    
    
31. MIYANO R, Shiraishi T
    Postoperative complications following prepectoral versus subpectoral tissue expander placement in immediate breast reconstruction: a retrospective study from Japan.
    Breast Cancer. 2026;33:147-155.
    PubMed         Abstract available
    
    
32. PARK JE, Lee T, Cho EH, Jang MA, et al
    Prevalence of germline CHEK2 variants in East Asians and Koreans based on population genomic databases.
    Breast Cancer. 2026;33:80-87.
    PubMed         Abstract available
    
    
33. IMOKAWA T, Satoh Y, Fujioka T, Takahashi K, et al
    Deep learning model with collage images for the segmentation of dedicated breast positron emission tomography images.
    Breast Cancer. 2026;33:17-24.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

34. GOU Y, Li Y, Wang Y, Ma H, et al
    Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker.
    Breast Cancer (Dove Med Press). 2025;17:1439-1461.
    PubMed         Abstract available
    
    
35. ANDRADE PACHNICKI JP, Cayet CM, Dos Santos DAH, Junkes GB, et al
    Introducing a New Hypothesis in the Genesis of Breast Cancer: An Integrative Review.
    Breast Cancer (Dove Med Press). 2025;17:1493-1504.
    PubMed         Abstract available
    
    
36. KANG Y, Wang X, Liu Y, Cao J, et al
    Noncoding RNAs, Vital Players in Breast Cancer Metastasis.
    Breast Cancer (Dove Med Press). 2025;17:1463-1492.
    PubMed         Abstract available
    
    
37. CHEN L, Huang J, Chen X, Lan X, et al
    Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study.
    Breast Cancer (Dove Med Press). 2025;17:1427-1437.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

38. CHANCHOU M, Mouret-Reynier MA, Molnar I, Deshayes E, et al
    (18)F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.
    Breast Cancer Res. 2025;28:2.
    PubMed         Abstract available
    
    
39. JIANG L, Xu J, Jiang C, Jia Y, et al
    BHLHE22, targeted by deubiquitinating enzyme OTUD3, exerts an antitumor role in triple-negative breast cancer progression via transcriptionally inhibiting CDT1.
    Breast Cancer Res. 2026 Jan 2. doi: 10.1186/s13058-025-02198.
    PubMed         Abstract available
    
    
40. PANAGOPOULOU M, Papadaki MA, Karaglani M, Theodosiou T, et al
    Nuovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer.
    Breast Cancer Res. 2026;28:1.
    PubMed         Abstract available
    
    
41. VAN BERCKELAER C, Van Laere S, Vermeulen C, Kockx M, et al
    The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology.
    Breast Cancer Res. 2026 Jan 5. doi: 10.1186/s13058-025-02192.
    PubMed         Abstract available
    
    
42. EKSTROM K, Riaz N, Larsson K, Nemeth A, et al
    Plasma extracellular vesicles reflect response and prognosis in patients with breast cancer undergoing neoadjuvant treatment.
    Breast Cancer Res. 2026 Jan 9. doi: 10.1186/s13058-025-02209.
    PubMed        
    
    
43. MARCHAL MI, Mutie PM, Azimi T, Deng YA, et al
    Distinct genetic profiles of obesity have different effects on breast cancer risk: leveraging Mendelian randomisation to interrogate causal pathways and identify mediating proteins.
    Breast Cancer Res. 2026 Jan 9. doi: 10.1186/s13058-025-02214.
    PubMed        
    
    
44. LEE JA, Lee HS, Jeon S, Kim D, et al
    Association between metabolic dysfunction-associated steatotic liver disease and breast cancer risk in Korean women: a nationwide population-based cohort study.
    Breast Cancer Res. 2026 Jan 7. doi: 10.1186/s13058-025-02211.
    PubMed        
    
    
45. KEHM RD, Lilge L, Walter EJ, Santella RM, et al
    Recreational physical activity and biomarkers of breast cancer risk in a cohort of adolescent girls.
    Breast Cancer Res. 2026 Jan 7. doi: 10.1186/s13058-025-02216.
    PubMed        
    
    
46. SHAW R, Cornwall D, Badal S, Powell LP, et al
    Molecular subtypes of breast cancer in Jamaican women: high prevalence of triple-negative and HER2 + disease.
    Breast Cancer Res. 2026 Jan 6. doi: 10.1186/s13058-025-02175.
    PubMed        
    
    
47. YAN P, Wu F, Afanasyeva Y, Arslan A, et al
    Premenopausal serum midkine levels and risk of estrogen receptor positive breast cancer: a prospective, nested case-control study.
    Breast Cancer Res. 2026 Jan 6. doi: 10.1186/s13058-025-02210.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

48. GLATT T, Leggat-Barr K, Seth N, Heditsian D, et al
    RISE UP for breast cancer 2024: conference highlights & takeaways.
    Breast Cancer Res Treat. 2026;215:53.
    PubMed         Abstract available
    
    
49. ARTIGNAN J, Capmas P, Panjo H, Bejarano-Quisoboni D, et al
    Changes in compliance with cardiovascular medication after a breast cancer diagnosis: a latent class trajectory analysis using French nationwide data.
    Breast Cancer Res Treat. 2026;215:52.
    PubMed         Abstract available
    
    
50. LIU J, Chu F, Yao L, Sun J, et al
    Risk of second non-breast primary cancer in Chinese breast cancer patients with germline BRCA1/2 pathogenic variants.
    Breast Cancer Res Treat. 2026;215:50.
    PubMed         Abstract available
    
    
51. TAHANEY WM, Lanier A, Qian J, Moyer CL, et al
    Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2026;215:49.
    PubMed         Abstract available
    
    
52. LIU S, Du B, Zhang M, Zhai D, et al
    Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression.
    Breast Cancer Res Treat. 2026;215:51.
    PubMed         Abstract available
    
    
53. HJORTH S, Vandraas KF, Trewin-Nybraten CB, Botteri E, et al
    Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently.
    Breast Cancer Res Treat. 2026;215:54.
    PubMed         Abstract available
    
    
54. CHEN EL, Heiling H, Li T, Bellon JR, et al
    Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.
    Breast Cancer Res Treat. 2026;215:55.
    PubMed         Abstract available
    
    

    
    Breast J

55. SHEN Y, Zhang J, Liu Y, Cai H, et al
    Nerve Grafts in Breast Reconstruction: A Narrative Review.
    Breast J. 2025;2025:1035158.
    PubMed         Abstract available
    
    

    
    Cancer

56. LAWRENCE L
    Joint guideline update recommendations for postmastectomy radiation therapy: The guideline task force identified several key radiation therapy questions for patients with breast cancer who undergo mastectomy.
    Cancer. 2026;132:e70178.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

57. IKEGAMI K, Makihara RA, Katsuya Y, Suzuki T, et al
    Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events.
    Cancer Chemother Pharmacol. 2026;96:3.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

58. MOONEY SJ, Rundle AG
    Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors?
    Cancer Epidemiol Biomarkers Prev. 2026;35:138-143.
    PubMed         Abstract available
    
    
59. WANG SS, Wu J, Wu AH, Cheng I, et al
    Associations of Proximity to Superfund Sites and Air Pollution with Breast Cancer Subtypes: Clues from a Case-Case Study and Call for Longitudinal Studies.
    Cancer Epidemiol Biomarkers Prev. 2026;35:7-9.
    PubMed         Abstract available
    
    

    
    Cancer Lett

60. CROSS CB, Bowen JM, Leifert WR, Beale DJ, et al
    Pre-treatment Gut Microbiome and Salivary Metabolome Signatures Associate with Chemotherapy-Induced Cognitive Decline in Women with Breast Cancer: A Prospective Pilot Study.
    Cancer Lett. 2026 Jan 7:218234. doi: 10.1016/j.canlet.2025.218234.
    PubMed        
    
    

    
    Cancer Res

61. SOTTNIK JL, Shackleford MT, Nesiba CS, Richer AL, et al
    Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition.
    Cancer Res. 2026 Jan 9. doi: 10.1158/0008-5472.CAN-25-1217.
    PubMed         Abstract available
    
    
62. HERZOG SK, Stevens JH, Gu G, Grimm SL, et al
    Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.
    Cancer Res. 2026 Jan 7. doi: 10.1158/0008-5472.CAN-24-3891.
    PubMed         Abstract available
    
    
63. PERURENA N, Watanabe M, Schade AE, Brown W, et al
    EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Pro-apoptotic Regulators.
    Cancer Res. 2026 Jan 5. doi: 10.1158/0008-5472.CAN-24-3113.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

64. BADHAI C, Singh MR, Dwivedi SD, Singh D, et al
    ADAM and ADAMTS Proteases in Breast Cancer: Molecular Mechanisms and Therapeutic Implications.
    Clin Breast Cancer. 2025;26:17-35.
    PubMed         Abstract available
    
    
65. YIJUN H, Huixing L, Liping W
    Research Progress of Radiotherapy Combined With Immunotherapy for Breast Cancer: Mechanism Exploration and Clinical Translation.
    Clin Breast Cancer. 2025;26:1-16.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

66. JHAVERI K, Loi S, Hamilton E, Schmid P, et al
    DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer.
    Clin Cancer Res. 2026 Jan 8. doi: 10.1158/1078-0432.CCR-25-0874.
    PubMed         Abstract available
    
    
67. JURIC D, Song K, Johnson RM, Accordino MK, et al
    PI3Kalpha Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
    Clin Cancer Res. 2026;32:56-75.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

68. HANSSON E, Sunden M, Wadsten C, Rask G, et al
    Breast cancer liver metastases and the impact of receptor expression on survival.
    Clin Exp Metastasis. 2026;43:8.
    PubMed        
    
    

    
    Eur J Cancer

69. YAN Y, Xue X, Xie J, Liu J, et al
    Prediction of HER2 changes post-neoadjuvant therapy based on fusion of ultrasound radiomics and clinicopathological features empowered by explainable AI: A multicenter study.
    Eur J Cancer. 2026;232:116158.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

70. SNELLEN TIM, Baas GSNJ, Scholten AN, Dezentje VO, et al
    Tailoring axillary treatment in patients with isolated locoregional recurrent breast cancer.
    Eur J Surg Oncol. 2025;52:111375.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

71. HOFFMANN RJ, Bensen A, Dane M, Arterberry J, et al
    S-Nitrosylated COX-2 is a microenvironment-regulated breast cancer cell biomarker of mesenchymal phenotypes.
    Exp Cell Res. 2026 Jan 7:114888. doi: 10.1016/j.yexcr.2026.114888.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

72. DOMCHEK SM
    Therapeutic Considerations in Early-Stage, Estrogen Receptor-Positive, BRCA-Associated Breast Cancer.
    J Clin Oncol. 2026 Jan 5:JCO2502428. doi: 10.1200/JCO-25-02428.
    PubMed        
    
    

    
    J Natl Cancer Inst

73. SHERMAN ME, Etievant L, Vierkant RA, Winham SJ, et al
    Postpartum breast cancer: evidence for a distinct phenotype.
    J Natl Cancer Inst. 2026 Jan 9:djag003. doi: 10.1093.
    PubMed         Abstract available
    
    
74. LEHRER S
    Re: Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2026 Jan 8:djaf339. doi: 10.1093.
    PubMed        
    
    
75. LOWRY KP, Jeong HE, Kim KH, Hughes KS, et al
    Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review.
    J Natl Cancer Inst. 2026 Jan 7:djag002. doi: 10.1093.
    PubMed         Abstract available
    
    
76. IM C, Hasan H, Srinivasan A, Stene E, et al
    Breast cancer recurrence and mortality among survivors of childhood cancer.
    J Natl Cancer Inst. 2026 Jan 7:djag005. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

77. AKCA U, Song PN, Devalankar D, Yasui N, et al
    Preclinical Comparison of (18)F-Labeled Amino Acids Targeting Different Transporter Systems for PET Imaging of Triple-Negative Breast Cancer.
    J Nucl Med. 2026 Jan 8:jnumed.125.270225. doi: 10.2967/jnumed.125.270225.
    PubMed         Abstract available
    
    

    
    J Pathol

78. LU X, Luo B, Wei Y, Zhang W, et al
    Integration of histopathological characteristics by machine learning improves the prediction of neoadjuvant immunochemotherapy response in triple-negative breast cancer.
    J Pathol. 2026 Jan 6. doi: 10.1002/path.70022.
    PubMed         Abstract available
    
    

    
    Mod Pathol

79. MCKELVEY B, Torres-Saavedra PA, Li J, Broeckx G, et al
    Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images.
    Mod Pathol. 2026 Jan 5:100944. doi: 10.1016/j.modpat.2025.100944.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

80. MUSSIN NM, Zhilisbayeva KR, Baspakova A, Ishimova LA, et al
    Mesenchymal stem cell-derived extracellular vesicle therapy in breast cancer: A systematic review and meta-analysis of in vitro studies.
    Mol Ther Oncol. 2025;34:201107.
    PubMed         Abstract available
    
    

    
    Nature

81. ABBOTT KL, Subudhi S, Ferreira R, Gultekin Y, et al
    Nutrient requirements of organ-specific metastasis in breast cancer.
    Nature. 2026 Jan 7. doi: 10.1038/s41586-025-09898.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

82. PARMAR P, Karadal-Ferrena B, Shukla S, Miller A, et al
    Racial disparity in pro-metastatic tumor microenvironment in treatment naive breast cancer.
    NPJ Breast Cancer. 2026;12:3.
    PubMed         Abstract available
    
    

    
    Oncogene

83. TAYA M, Fishman D, Kanani F, Zinger L, et al
    The role of the SLC25A15 transporter in the formation of liver metastasis in ESR1-mutated breast cancer.
    Oncogene. 2026 Jan 3. doi: 10.1038/s41388-025-03640.
    PubMed         Abstract available
    
    

    
    Oncology

84. BLANTER J, Kocyigit H, Kowtha L, Harigopal M, et al
    Prescribing trends of adjuvant neratinib in hormone-positive HER2 positive breast cancer.
    Oncology. 2026 Jan 7:1-10. doi: 10.1159/000549970.
    PubMed         Abstract available
    
    

    
    PLoS One

85. ZHAO X, Li J, Hu N, Wu X, et al
    Establishment of an amino acid metabolism related signature for prognostic and therapeutic sensitivity prediction in breast cancer by machine learning.
    PLoS One. 2026;21:e0340586.
    PubMed         Abstract available
    
    
86. FERRE F, Seghieri C, Sarv Ahrabi S, Burattin A, et al
    Enhancing quality and decision-making for care pathways: An application of process mining in cancer care.
    PLoS One. 2026;21:e0339788.
    PubMed         Abstract available
    
    
87. LI J, Zhao B, Chen Y, Wang G, et al
    Research on the establishment of a four-classification model for breast mass ultrasound images based on transfer learning.
    PLoS One. 2026;21:e0340111.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

88. MORRISSEY RL, McDaniel JM, Chau GP, Su X, et al
    Elucidating cooperative genetic events in DCIS progression in mutant p53-driven breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2526544123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.